IMETELSTAT – Treatment for MDS and MF
Hello, I am a former caregiver who is interested in informing all patients, their family members and any medical practitioners here about IMETELSTAT. It is an exciting new drug targeting telomeres in treating MDS and MF that is being developed by GERON. It finished P2 trials with REMARKABLE results. Where there are very few options for treatment this looks to be a medical break through with very few, and it should be noted REVERSIBLE side effects. Phase 3 trials are set to begin in mid-2019, which means global recruitment will begin very soon. IMerge is a two-part clinical trial of IMETELSTAT in transfusion dependent patients with Low or Intermediate-1 risk, also referred to as lower risk, MDS, who have relapsed after or are refractory to prior treatment with an ESA. In October 2017 this was given the green light for FDA fast track status. Please read the data review from this year’s ASH symposium on Dec 2018 I have provided in the link below:
https://seekingalpha.com/article/4227473-geron-corporation-gern-investor-presentation-slideshow?dr=1
After reviewing please contact GERON to find out when recruitment will begin and where recruitment sites will be available – https://www.geron.com/about/contact/
Phase 2 location sites can be found at – https://clinicaltrials.gov/ct2/show/study/NCT02598661?show_locs=Y#locn
(as of this writing I am not sure if site locations for P3 will be the same)
IMETELSTAT has the potential of someday targeting 90% of all cancers as described in the abstract below:
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4633-x
Even if IMETELSTAT is not an option for you, I implore you to do all the research you possibly can for what ever condition you may be facing. Time is of the essence and most crucial when dealing with many cancers, especially aggressive blood borne ones. I wish all of you the best in your treatment and hope the information I have provided can help in any way possible. All the best. Kmall
.
